Marc Williams
Medical · Pueblo, CONPI 1659542926
Payments from drug & device makers
Across 282 payments — averaging $17.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$842
- AbbVie$689
- Amgen$509
- Lilly USA, LLC$342
- AstraZeneca$239
- Boehringer Ingelheim$196
- plus $2K from 33 others
What the payments were for
- Food & beverage$4,811100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,822 in reported general payments places this provider in the 85th percentile of 766 medical providers in Colorado.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 68 | $101,244 |
| MounjaroTirzepatide | 40 | $46,094 |
| EliquisApixaban | 38 | $40,214 |
| FarxigaDapagliflozin Propanediol | 27 | $29,461 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $27,419 |
| Tresiba Flextouch U-200Insulin Degludec | 28 | $26,022 |
| MyrbetriqMirabegron | 24 | $24,725 |
| Repatha SureclickEvolocumab | 22 | $21,350 |
| TrulicityDulaglutide | 12 | $18,680 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 55 | $17,011 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 56 | $12,277 |
| JardianceEmpagliflozin | 13 | $10,932 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 24 | $6,832 |
| Atorvastatin Calcium | 263 | $2,313 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $2,203 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $842 | $101,24468 claims |
| Lilly USA, LLCMounjaro, Trulicity | $342 | $64,77452 claims |
| GSKTrelegy Ellipta, Arexvy, Shingrix | $59 | $56,707137 claims |
| PfizerEliquis | $183 | $40,21438 claims |
| AstraZenecaFarxiga | $239 | $29,46127 claims |
| Astellas Pharma US IncMyrbetriq | $189 | $24,72524 claims |
| Boehringer IngelheimJardiance | $196 | $10,93213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 766 medical providers in Colorado.
Other medical in Pueblo
- Christen KutzColorado Springs$2.4M
- Amanda MixonFort Collins$342K
- Kristin RyggColorado Springs$255K
- Jordan MastDenver$247K
- John NovakAurora$173K
- Michelle BarnettColorado Springs$138K
- Michael JacobsonFort Collins$131K
- Lindsey TunstallAurora$87K
- Jennifer NafzigerHighlands Ranch$80K
- Daniel TaylorDenver$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.